

# David Katzenstein

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6507820/publications.pdf>

Version: 2024-02-01

124  
papers

5,817  
citations

61984

43  
h-index

79698

73  
g-index

127  
all docs

127  
docs citations

127  
times ranked

5384  
citing authors

#	ARTICLE	IF	CITATIONS
1	Abacavirâ€“Lamivudine versus Tenofovirâ€“Emtricitabine for Initial HIV-1 Therapy. <i>New England Journal of Medicine</i> , 2009, 361, 2230-2240.	27.0	289
2	Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1. <i>Annals of Internal Medicine</i> , 2011, 154, 445.	3.9	287
3	The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan. <i>Antiviral Therapy</i> , 2000, 5, 41-48.	1.0	263
4	Hierarchical Targeting of Subtype C Human Immunodeficiency Virus Type 1 Proteins by CD8 + T Cells: Correlation with Viral Load. <i>Journal of Virology</i> , 2004, 78, 3233-3243.	3.4	202
5	HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirâ€“ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed. <i>Annals of Internal Medicine</i> , 1999, 131, 813.	3.9	198
6	Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. <i>PLoS Medicine</i> , 2015, 12, e1001810.	8.4	188
7	The Incidence and Correlates of Symptomatic and Asymptomatic <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoeae</i> Infections in Selected Populations in Five Countries. <i>Sexually Transmitted Diseases</i> , 2011, 38, 503-509.	1.7	162
8	Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for Initial Treatment of HIV: Final Results. <i>Journal of Infectious Diseases</i> , 2011, 204, 1191-1201.	4.0	157
9	Human Immunodeficiency Virus Type 1 Populations in Blood and Semen. <i>Journal of Virology</i> , 1998, 72, 617-623.	3.4	157
10	Sustainable HIV treatment in Africa through viral-load-informed differentiated care. <i>Nature</i> , 2015, 528, S68-S76.	27.8	141
11	New Concepts of Amebic Liver Abscess Derived from Hepatic Imaging, Serodiagnosis, and Hepatic Enzymes in 67 Consecutive Cases in San Diego. <i>Medicine (United States)</i> , 1982, 61, 237-246.	1.0	137
12	Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. <i>Aids</i> , 1998, 12, 2295-2303.	2.2	113
13	Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy. <i>Aids</i> , 2004, 18, 1503-1511.	2.2	106
14	Prevalence and Incidence of Herpes Simplex Virus Type 2 Infection among Male Zimbabwean Factory Workers. <i>Journal of Infectious Diseases</i> , 1999, 180, 1459-1465.	4.0	100
15	Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa. <i>Aids</i> , 2010, 24, 1679-1687.	2.2	100
16	Mortality in the First 2 Years among Infants Born to Human Immunodeficiency Virus-Infected Women in Harare, Zimbabwe. <i>Journal of Infectious Diseases</i> , 1998, 178, 109-113.	4.0	96
17	Randomized Study of Saquinavir with Ritonavir or Nelfinavir Together with Delavirdine, Adefovir, or Both in Human Immunodeficiency Virusâ€“Infected Adults with Virologic Failure on Indinavir: AIDS Clinical Trials Group Study 359. <i>Journal of Infectious Diseases</i> , 2000, 182, 1375-1384.	4.0	95
18	CCR5- and CXCR4-Tropic Subtype C Human Immunodeficiency Virus Type 1 Isolates Have a Lower Level of Pathogenic Fitness than Other Dominant Group M Subtypes: Implications for the Epidemic. <i>Journal of Virology</i> , 2009, 83, 5592-5605.	3.4	86

#	ARTICLE	IF	CITATIONS
19	HIV seroincidence and correlated of seroconversion in a cohort of male factory workers in Harare, Zimbabwe. <i>Aids</i> , 1996, 10, 895-902.	2.2	84
20	Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa. <i>PLoS ONE</i> , 2011, 6, e17518.	2.5	84
21	Sex-Based Differences in Saquinavir Pharmacology and Virologic Response in AIDS Clinical Trials Group Study 359. <i>Journal of Infectious Diseases</i> , 2004, 189, 1176-1184.	4.0	81
22	Association between Human Immunodeficiency Virus and Herpes Simplex Virus Type 2 Seropositivity among Male Factory Workers in Zimbabwe. <i>Journal of Infectious Diseases</i> , 1998, 177, 481-484.	4.0	79
23	Discordances between Interpretation Algorithms for Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors of Human Immunodeficiency Virus Are Subtype Dependent. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 694-701.	3.2	78
24	Drug resistance in non-subtype B HIV-1. <i>Journal of Clinical Virology</i> , 2004, 29, 152-159.	3.1	77
25	Factors in the Delayed HIV Presentation of Immigrants in Northern California: Implications for Voluntary Counseling and Testing Programs. <i>Journal of Immigrant and Minority Health</i> , 2006, 9, 49-54.	1.6	74
26	HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing. <i>PLoS ONE</i> , 2015, 10, e0145772.	2.5	72
27	Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. <i>AIDS Reviews</i> , 2003, 5, 25-35.	1.0	72
28	Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. <i>Aids</i> , 2001, 15, 1125-1132.	2.2	69
29	Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study. <i>BMC Public Health</i> , 2011, 11, 88.	2.9	69
30	Nucleic Acid Template and the Risk of a PCR-Induced HIV-1 Drug Resistance Mutation. <i>PLoS ONE</i> , 2010, 5, e10992.	2.5	62
31	Human Immunodeficiency Virus Type 1 RNA Shedding in the Female Genital Tract. <i>Journal of Infectious Diseases</i> , 1998, 177, 1100-1103.	4.0	61
32	HIV Type 1 Genotypic Variation in an Antiretroviral Treatment-Naive Population in Southern India. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 301-305.	1.1	60
33	Metabolic and Immune Activation Effects of Treatment Interruption in Chronic HIV-1 Infection: Implications for Cardiovascular Risk. <i>PLoS ONE</i> , 2008, 3, e2021.	2.5	56
34	The extent of non-adherence in a large AIDS clinical trial using plasma dideoxynucleoside concentrations as a marker. <i>Aids</i> , 1998, 12, 2305-2311.	2.2	55
35	Primary Drug Resistance in South Africa: Data from 10 Years of Surveys. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 558-565.	1.1	51
36	Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000-2016: A Pooled Sequence Analysis. <i>EClinicalMedicine</i> , 2019, 9, 26-34.	7.1	51

#	ARTICLE	IF	CITATIONS
37	Short Communication: Geographic and Demographic Differences in the Frequency of Human Cytomegalovirus gB Genotypes 1&#x201c;4 in Immunocompromised Patients. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 533-536.	1.1	50
38	Detection of Kaposi's Sarcoma&#x201c;Associated Herpesvirus in Oral and Genital Secretions of Zimbabwean Women. <i>Journal of Infectious Diseases</i> , 2000, 181, 1785-1790.	4.0	49
39	Novel and Promiscuous CTL Epitopes in Conserved Regions of Gag Targeted by Individuals with Early Subtype C HIV Type 1 Infection from Southern Africa. <i>Journal of Immunology</i> , 2004, 173, 4607-4617.	0.8	49
40	Impact of Drug Resistance-Associated Amino Acid Changes in HIV-1 Subtype C on Susceptibility to Newer Nonnucleoside Reverse Transcriptase Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 960-971.	3.2	48
41	Competing drug&#x201c;drug interactions among multidrug antiretroviral regimens used in the treatment of HIV-infected subjects: ACTG 884. <i>Aids</i> , 2000, 14, 2495-2501.	2.2	45
42	Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe. <i>Aids</i> , 2009, 23, 2523-2532.	2.2	45
43	The evaluation of the HIV/AIDS Drug Access Initiatives in C&#x201c;te D&#x201c;Ivoire, Senegal and Uganda. <i>Aids</i> , 2003, 17, S1-S4.	2.2	44
44	Quality of life, psychosocial health, and antiretroviral therapy among HIV-positive women in Zimbabwe. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2009, 21, 1517-1527.	1.2	44
45	HIV disclosure patterns, predictors, and psychosocial correlates among HIV positive women in Zimbabwe. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2012, 24, 358-368.	1.2	44
46	Evaluation of two human immunodeficiency virus-1 genotyping systems: ViroSeq&#x201c;,c 2.0 and an in-house method. <i>Journal of Virological Methods</i> , 2009, 159, 211-216.	2.1	43
47	Isolated <i>Candida</i> arthritis: Report of a case and definition of a distinct clinical syndrome. <i>Arthritis and Rheumatism</i> , 1985, 28, 1421-1424.	6.7	41
48	HIV Drug Resistance Mutations in Proviral DNA from a Community Treatment Program. <i>PLoS ONE</i> , 2015, 10, e0117430.	2.5	39
49	Transmitted HIV Drug Resistance Is High and Longstanding in Metropolitan Washington, DC. <i>Clinical Infectious Diseases</i> , 2016, 63, 836-843.	5.8	37
50	Botulism, type A, and treatment with guanidine. <i>Annals of Neurology</i> , 1979, 6, 69-71.	5.3	36
51	A Pilot Study Evaluating Time to CD4 T-cell Count <350 cells/mm <sup>3</sup> After Treatment Interruption Following Antiretroviral Therapy &#x201c; Interleukin 2: Results of ACTG A5102. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2006, 42, 140-148.	2.1	35
52	TREAT Asia Quality Assessment Scheme (TAQAS) to standardize the outcome of HIV genotypic resistance testing in a group of Asian laboratories. <i>Journal of Virological Methods</i> , 2009, 159, 185-193.	2.1	35
53	An evaluation of dipstick-dot immunoassay in the detection of antibodies to HIV-1 and 2 in Zimbabwe. <i>Tropical Medicine and International Health</i> , 1997, 2, 83-88.	2.3	34
54	Drug Susceptibility and Resistance Mutations After First-Line Failure in Resource Limited Settings. <i>Clinical Infectious Diseases</i> , 2014, 59, 706-715.	5.8	34

#	ARTICLE	IF	CITATIONS
55	Assessing Resistance Costs of Antiretroviral Therapies via Measures of Future Drug Options. <i>Journal of Infectious Diseases</i> , 2003, 188, 1001-1008.	4.0	33
56	Drug Resistance in Plasma and Breast Milk after Single-Dose Nevirapine in Subtype C HIV Type 1: Population and Clonal Sequence Analysis. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 1055-1061.	1.1	30
57	Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine. <i>Journal of Infectious Diseases</i> , 2013, 207, S70-S77.	4.0	30
58	Outcomes by Sex Following Treatment Initiation With Atazanavir Plus Ritonavir or Efavirenz With Abacavir/Lamivudine or Tenofovir/Emtricitabine. <i>Clinical Infectious Diseases</i> , 2014, 58, 555-563.	5.8	30
59	An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	30
60	Drug Resistance Patterns and Virus Re-Suppression among HIV-1 Subtype C Infected Patients Receiving Non-Nucleoside Reverse Transcriptase Inhibitors in South Africa. <i>Journal of AIDS &amp; Clinical Research</i> , 2011, 02, .	0.5	30
61	A Phase I, placebo-controlled trial of multi-dose recombinant human interleukin-12 in patients with HIV infection. <i>Aids</i> , 2002, 16, 1147-1154.	2.2	28
62	Viremia and HIV-1 Drug Resistance Mutations Among Patients Receiving Second-Line Highly Active Antiretroviral Therapy in Chennai, Southern India. <i>Clinical Infectious Diseases</i> , 2012, 54, 995-1000.	5.8	28
63	HIV-1 Drug Resistance and Third-Line Therapy Outcomes in Patients Failing Second-Line Therapy in Zimbabwe. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy005.	0.9	28
64	Weighted Phenotypic Susceptibility Scores Are Predictive of the HIV-1 RNA Response in Protease Inhibitor-Experienced HIV-1 Infected Subjects. <i>Journal of Infectious Diseases</i> , 2004, 190, 886-893.	4.0	26
65	Genotypic Susceptibility Scores and HIV Type 1 RNA Responses in Treatment-Experienced Subjects with HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2008, 24, 685-694.	1.1	26
66	Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. <i>Antiviral Therapy</i> , 2009, 14, 1005-1009.	1.0	26
67	Human Immunodeficiency Virus Reverse Transcriptase Codon 215 Mutations Diminish Virologic Response to Didanosine-Zidovudine Therapy in Subjects with Non-Syncytium-Inducing Phenotype. <i>Journal of Infectious Diseases</i> , 1996, 174, 854-857.	4.0	25
68	Short Communication: Viral Dynamics and CD4+ T Cell Counts in Subtype C Human Immunodeficiency Virus Type 1-Infected Individuals from Southern Africa. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 285-291.	1.1	24
69	Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 76, 55-59.	2.1	24
70	Plasma carnitine in HIV-associated neuropathy. <i>Aids</i> , 2001, 15, 2207-2208.	2.2	24
71	Placental Malaria and Mother-to-Child Transmission of Human Immunodeficiency Virus-1 in Rural Rwanda. <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 85, 202-206.	1.4	23
72	Sexual behaviour and risk assessment of HIV seroconvertors among urban male factory workers in Zimbabwe. <i>Social Science and Medicine</i> , 1998, 47, 1431-1443.	3.8	19

#	ARTICLE	IF	CITATIONS
73	Fertility desires and condom use among HIV-positive women at an antiretroviral roll-out program in Zimbabwe. <i>African Journal of Reproductive Health</i> , 2010, 14, 27-35.	1.1	19
74	Lack of Evidence for Frequent Heterosexual Transmission of Human Herpesvirus 8 in Zimbabwe. <i>Clinical Infectious Diseases</i> , 2009, 48, 1601-1608.	5.8	18
75	HIV-1 Amino Acid Changes Among Participants With Virologic Failure: Associations With First-line Efavirenz or Atazanavir Plus Ritonavir and Disease Status. <i>Journal of Infectious Diseases</i> , 2012, 206, 1920-1930.	4.0	18
76	Envelope Coreceptor Tropism, Drug Resistance, and Viral Evolution Among Subtype C HIV-1-Infected Individuals Receiving Nonsuppressive Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 9-18.	2.1	17
77	Combination therapies for HIV infection and genomic drug resistance. <i>Lancet, The</i> , 1997, 350, 970-971.	13.7	16
78	HIV diversity and drug resistance from plasma and non-plasma analytes in a large treatment programme in western Kenya. <i>Journal of the International AIDS Society</i> , 2014, 17, 19262.	3.0	16
79	Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy. <i>Aids</i> , 2019, 33, 1729-1737.	2.2	16
80	Effect of Therapeutic Immunization With Recombinant gp160 HIV-1 Vaccine on HIV-1 Proviral DNA and Plasma RNA. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1997, 15, 269-274.	0.3	16
81	Perceived risks and benefits of HIV testing, and predictors of acceptance of HIV counselling and testing among pregnant women in Zimbabwe. <i>International Journal of STD and AIDS</i> , 2006, 17, 835-841.	1.1	15
82	Diversity, Drug Resistance, and the Epidemic of Subtype C HIV-1 in Africa. <i>Journal of Infectious Diseases</i> , 2006, 194, S45-S50.	4.0	14
83	Community-based self-collected human papillomavirus screening in rural Zimbabwe. <i>BMC Public Health</i> , 2019, 19, 603.	2.9	14
84	Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe. <i>International Journal of Infectious Diseases</i> , 2019, 78, 65-71.	3.3	14
85	Title is missing!. <i>AIDS and Behavior</i> , 2000, 4, 63-70.	2.7	13
86	A Simple Phosphate-Buffered-Saline-Based Extraction Method Improves Specificity of HIV Viral Load Monitoring Using Dried Blood Spots. <i>Journal of Clinical Microbiology</i> , 2017, 55, 2172-2179.	3.9	13
87	Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 566-573.	1.1	13
88	Surveillance of Transmitted Antiretroviral Drug Resistance among HIV-1 Infected Women Attending Antenatal Clinics in Chitungwiza, Zimbabwe. <i>PLoS ONE</i> , 2011, 6, e21241.	2.5	13
89	Comparison of Gynecologic History and Laboratory Results in HIV-Positive Women With CD4+ Lymphocyte Counts Between 200 and 500 Cells/ $\mu$ l and Below 100 Cells/ $\mu$ l. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1999, 20, 455-462.	0.3	12
90	Durability of Response to Treatment among Antiretroviral-Experienced Subjects: 48-Week Results from AIDS Clinical Trials Group Protocol 359. <i>Journal of Infectious Diseases</i> , 2002, 186, 626-633.	4.0	12

#	ARTICLE	IF	CITATIONS
91	Learning and doing: operational research and access to HIV treatment in Africa. <i>Aids</i> , 2010, 24, S1-S4.	2.2	12
92	Zidovudine (AZT) Monotherapy Selects for the A360V Mutation in the Connection Domain of HIV-1 Reverse Transcriptase. <i>PLoS ONE</i> , 2012, 7, e31558.	2.5	12
93	Community Based Antiretroviral Treatment in Rural Zimbabwe. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1185-1191.	1.1	11
94	HIV-1 RNA Levels and Antiretroviral Drug Resistance in Blood and Non-Blood Compartments from HIV-1 Infected Men and Women enrolled in AIDS Clinical Trials Group Study A5077. <i>PLoS ONE</i> , 2014, 9, e93537.	2.5	10
95	Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2016, 213, 250-256.	4.0	10
96	Capacity building and predictors of success for HIV-1 drug resistance testing in the Asia-Pacific region and Africa. <i>Journal of the International AIDS Society</i> , 2013, 16, 18580.	3.0	9
97	Evaluating an enhanced adherence intervention among HIV positive adolescents failing atazanavir/ritonavir-based second line antiretroviral treatment at a public health clinic. <i>Journal of AIDS and HIV Research (Online)</i> , 2017, 9, 17-30.	0.4	9
98	Combining Phylogenetic and Network Approaches to Identify HIV-1 Transmission Links in San Mateo County, California. <i>Frontiers in Microbiology</i> , 2018, 9, 2799.	3.5	9
99	Knowledge, attitudes, and practices of cervical Cancer screening among HIV-positive and HIV-negative women participating in human papillomavirus screening in rural Zimbabwe. <i>BMC Women's Health</i> , 2020, 20, 153.	2.0	9
100	Lower CD4 Cell Count and Higher Virus Load, but Not Antiretroviral Drug Resistance, Are Associated with AIDS-Defining Events and Mortality: An ACTG Longitudinal Linked Randomized Trials (ALLRT) Analysis. <i>HIV Clinical Trials</i> , 2011, 12, 79-88.	2.0	8
101	Diagnostic Accuracy of Pan-Degenerate Amplification and Adaptation Assay for HIV-1 Drug Resistance Mutation Analysis in Low- and Middle-Income Countries. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	8
102	Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 776-783.	1.1	8
103	HIV-1 Genetic Diversity and Natural Polymorphisms of the Integrase Gene in Integrase Inhibitor-Naive Patients in Harare, Zimbabwe. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 954-961.	1.1	7
104	Long-Term Effects Of Interleukin-2 On Cd4 Cell Counts In Human Immunodeficiency Virus-Infected Patients. <i>Journal of Infectious Diseases</i> , 1994, 170, 1044-1046.	4.0	6
105	Safety, Pharmacokinetics, and Antiviral Response of CD4-Immunoglobulin G by Intravenous Bolus in AIDS and AIDS-Related Complex. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1995, 10, 150-156.	0.3	6
106	Presentation and outcome of suspected sepsis in a high-HIV burden, high antiretroviral coverage setting. <i>International Journal of Infectious Diseases</i> , 2020, 96, 276-283.	3.3	6
107	Prenatal Transmission of Subtype C HIV-1 in Zimbabwe: HIV-1 RNA and DNA in Maternal and Cord Blood. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 25, 390-397.	2.1	5
108	Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 748-750.	1.1	5



#	ARTICLE	IF	CITATIONS
109	Drug Resistance Mutations from Whole Blood Proviral DNA Among Patients on Antiretroviral Drugs in Zimbabwe. <i>Current HIV Research</i> , 2014, 12, 309-316.	0.5	5
110	Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202. <i>HIV Clinical Trials</i> , 2013, 14, 284-291.	2.0	4
111	HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing. <i>Journal of Virological Methods</i> , 2017, 243, 151-157.	2.1	4
112	Clinical signs and symptoms in the assessment of immunodeficiency in men with subtype C HIV infection in Harare, Zimbabwe. <i>HIV Clinical Trials</i> , 2002, 3, 148-154.	2.0	3
113	Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5). <i>Aids</i> , 2010, 24, 1063-1064.	2.2	3
114	Viral load care of HIV-1 infected children and adolescents: A longitudinal study in rural Zimbabwe. <i>PLoS ONE</i> , 2021, 16, e0245085.	2.5	3
115	Editorial Commentary: Among the Devils in the Details Are Protease Sequence, Susceptibility, and Structure in CRF02_AG Viruses. <i>Clinical Infectious Diseases</i> , 2005, 41, 252-254.	5.8	2
116	Non-Nucleoside Phenotypic Hypersusceptibility Cut-Point Determination from ACTG 359. <i>HIV Clinical Trials</i> , 2007, 8, 63-67.	2.0	2
117	The point of point-of-care testing. <i>Lancet, The</i> , 2011, 378, 1532-1533.	13.7	2
118	Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 181-185.	2.1	2
119	Scaling Up Antiretroviral Therapy in Africa: Are We There Yet?: Table 1.. <i>Clinical Infectious Diseases</i> , 2015, 62, civ931.	5.8	1
120	Human Immunodeficiency Virus-1 Sequence Changes and Drug Resistance Mutation Among Virologic Failures of Lopinavir/Ritonavir Monotherapy: AIDS Clinical Trials Group Protocol A5230. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw154.	0.9	1
121	Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA). <i>Pan African Medical Journal</i> , 2021, 40, 57.	0.8	1
122	Vertical Transmission of HIV in Africa: Diagnostic Testing and New Interventions. <i>HIV Clinical Trials</i> , 2000, 1, 51-57.	2.0	0
123	The longer the better? Four years of durable, initially boosted protease treatment. <i>Aids</i> , 2004, 18, 811-813.	2.2	0
124	Reverse Transcriptase Substitution at Codons 208 and 228 Among Treatment-Experienced HIV-1 Subtype-Câ€“Infected Indian Patients Is Strongly Associated With Thymidine Analogue Mutations. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, e26-e27.	2.1	0